Home > Insider Trading > Filing (0001209191-20-009861)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1478320	Adaptive Biotechnologies Corp	ADPT	Biological Products, (No Disgnostic Substances) (2836)	270907024

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1780649	M Chad Robins	C/O Adaptive Biotechnologies Corporation 1551 Eastlake Ave E Ste 200 Seattle WA 98102	Ceo And Chairman	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-02-13	11,120	$0.33	1,889,300	No	4	M	Direct
Common Stock	Disposition	2020-02-13	11,120	$31.56	1,878,180	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-02-13	11,120	$0.00	11,120	$0.33
Common Stock	Stock Option (Right to Buy)	Acquisiton	2020-02-13	300,000	$0.00	300,000	$31.71

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
713,280		2021-12-20	No	4	M	Direct
300,000		2030-02-13	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	500,000	Indirect	By HSR 2014 Mother's Trust U/T/A dated June 17, 2014
Common Stock	350,000	Indirect	By HSR 2017 Trust Trust for Descendants u/a/d November 10, 2017

Footnotes

These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.02 to 31.91, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The options are fully vested and exercisable.
The options will vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.